BARCELONA, Spain and DÜSSELDORF, Germany, July 24, 2026 -- Minoryx Therapeutics and Neuraxpharm Group, announce that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has...


PharmAbbie is developing drugs targeted at the pet market based on existing human formulations. The company is concentrating on therapeutic categories including pain and inflammation, infections, diarrhea, dermatology, and cardiovascular problems, intended to provide safe, efficacious and easy-to-administer drugs to improve the quality of life of companion animals and their guardians.
PharmAbbie
Groton, CT